Cargando…

Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators

Diabetic nephropathy (DN) is one of the most important medical complications in diabetic patients, which is an essential cause of end-stage renal disease in diabetic patients and still lacks effective medicines. Silent information regulator 1 (SIRT1) is closely related to the occurrence and developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jian, Chen, Qing-Qing, Huang, Ye, Li, Kai-Hang, Geng, Xiao-Ju, Wang, Tao, Lin, Qi-Si, Yao, Ruo-Si
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113817/
https://www.ncbi.nlm.nih.gov/pubmed/33995069
http://dx.doi.org/10.3389/fphar.2021.653233
_version_ 1783690942054662144
author Gao, Jian
Chen, Qing-Qing
Huang, Ye
Li, Kai-Hang
Geng, Xiao-Ju
Wang, Tao
Lin, Qi-Si
Yao, Ruo-Si
author_facet Gao, Jian
Chen, Qing-Qing
Huang, Ye
Li, Kai-Hang
Geng, Xiao-Ju
Wang, Tao
Lin, Qi-Si
Yao, Ruo-Si
author_sort Gao, Jian
collection PubMed
description Diabetic nephropathy (DN) is one of the most important medical complications in diabetic patients, which is an essential cause of end-stage renal disease in diabetic patients and still lacks effective medicines. Silent information regulator 1 (SIRT1) is closely related to the occurrence and development of DN. Activation of SIRT1 could significantly improve the symptoms of DN, while the activities of SIRT1 activators need to be further improved. Based on the crystal structure of SIRT1, structure and ligand-based approaches were carried out, and a lead compound 4,456–0661 (renamed as M1) was identified. Moreover, seven M1 analogues (6a-6g) were designed using a structure-based drug design strategy followed by bioactivity evaluation with SRTR2104 used as positive drugs. Among the target molecules, compounds M1, 6b, and 6d were proved to be potent SIRT1 activators, the activities of which are comparable to SRT2104. More importantly, compounds M1, 6b, and 6d could resist high glucose-induced apoptosis of HK-2 cells by activating SIRT1 and deacetylation of p53. Apart from the beneficial effect on apoptosis of DN, these compounds also alleviated high glucose stimulating inflammation response in HK-2 cells through SIRT1/NF-κB (p65) pathway. Consequently, M1, 6b, and 6d could be promising drug candidates for SIRT1 related diseases.
format Online
Article
Text
id pubmed-8113817
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81138172021-05-13 Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators Gao, Jian Chen, Qing-Qing Huang, Ye Li, Kai-Hang Geng, Xiao-Ju Wang, Tao Lin, Qi-Si Yao, Ruo-Si Front Pharmacol Pharmacology Diabetic nephropathy (DN) is one of the most important medical complications in diabetic patients, which is an essential cause of end-stage renal disease in diabetic patients and still lacks effective medicines. Silent information regulator 1 (SIRT1) is closely related to the occurrence and development of DN. Activation of SIRT1 could significantly improve the symptoms of DN, while the activities of SIRT1 activators need to be further improved. Based on the crystal structure of SIRT1, structure and ligand-based approaches were carried out, and a lead compound 4,456–0661 (renamed as M1) was identified. Moreover, seven M1 analogues (6a-6g) were designed using a structure-based drug design strategy followed by bioactivity evaluation with SRTR2104 used as positive drugs. Among the target molecules, compounds M1, 6b, and 6d were proved to be potent SIRT1 activators, the activities of which are comparable to SRT2104. More importantly, compounds M1, 6b, and 6d could resist high glucose-induced apoptosis of HK-2 cells by activating SIRT1 and deacetylation of p53. Apart from the beneficial effect on apoptosis of DN, these compounds also alleviated high glucose stimulating inflammation response in HK-2 cells through SIRT1/NF-κB (p65) pathway. Consequently, M1, 6b, and 6d could be promising drug candidates for SIRT1 related diseases. Frontiers Media S.A. 2021-04-28 /pmc/articles/PMC8113817/ /pubmed/33995069 http://dx.doi.org/10.3389/fphar.2021.653233 Text en Copyright © 2021 Gao, Chen, Huang, Li, Geng, Wang, Lin and Yao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Gao, Jian
Chen, Qing-Qing
Huang, Ye
Li, Kai-Hang
Geng, Xiao-Ju
Wang, Tao
Lin, Qi-Si
Yao, Ruo-Si
Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators
title Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators
title_full Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators
title_fullStr Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators
title_full_unstemmed Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators
title_short Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators
title_sort design, synthesis and pharmacological evaluation of naphthofuran derivatives as potent sirt1 activators
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113817/
https://www.ncbi.nlm.nih.gov/pubmed/33995069
http://dx.doi.org/10.3389/fphar.2021.653233
work_keys_str_mv AT gaojian designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators
AT chenqingqing designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators
AT huangye designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators
AT likaihang designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators
AT gengxiaoju designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators
AT wangtao designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators
AT linqisi designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators
AT yaoruosi designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators